| Title:
|
REGENERATIVE MEDICINE
HOUSE OF LORDS PAPER 23 SESSION 2013-14 |
| By: |
Great Britain: Parliament: House of Lords: Science and Technology Committee, The Stationery Office (Editor), Lord John Krebs |
| Format: |
Paperback |
| List price:
|
£15.50 |
|
We currently do not stock this item, please contact the publisher directly for
further information.
|
|
|
|
|
|
| ISBN 10: |
0108551105 |
| ISBN 13: |
9780108551109 |
| Publisher: |
TSO |
| Pub. date: |
1 July, 2013 |
| Series: |
House of Lords Papers |
| Pages: |
112 |
| Synopsis: |
Whilst the NHS makes the UK a potentially attractive place for international investment in regenerative medicine, problems in our regulatory arrangements and a lack of co-ordinated leadership on the issue is holding back the chance to deliver improvements. Research indicates that there is likely to be a GBP44bn to GBP54bn NHS funding gap by 2022 and that management of chronic disease accounts for around 75% of all UK health costs. Regenerative medicine has the potential to provide innovative treatments for a wide range of chronic diseases such as diabetes and heart disease, and such treatments could be a major benefit to the UK public purse as well as providing health benefits.The Committee makes a number of recommendations including: the Health Research Authority should take steps to streamline the overall regulatory system for regenerative medicine; the National Institute for Health Research should set up a regenerative medicine stream of its clinical research network to assist with design of clinical trials; the Department for Business, Innovation and Skills should invest in manufacturing facilities to support the scale-up of treatments in mid to late stage clinical development; the Department of Health should develop a strategy to ensure the NHS is ready to provide regenerative treatments; Government must explore innovative funding models to further support the field; and the National Institute for Health and Care Excellence (NICE) must review its evaluation process to ensure that regenerative treatments, which can have a high start-up cost but could represent big savings for the NHS in the long run, do not lose out on funding |
| Publication: |
UK |
| Imprint: |
TSO |
| Returns: |
Non-returnable |